We are live on ! Find out more
Victory Capital Management

Victory Capital Management Portfolio holdings

AUM $178B
1-Year Est. Return 37.23%
This Fund
S&P 500
This Quarter Est. Return
-1.67%
1 Year Est. Return
+37.23%
3 Year Est. Return
+100.22%
5 Year Est. Return
+128.39%
10 Year Est. Return
+575.99%
AUM
$100B
AUM Growth
-$8.74B
Cap. Flow
-$1.7B
Cap. Flow %
-1.7%
Top 10 Hldgs %
9.77%
Holding
2,893
New
146
Increased
1,494
Reduced
995
Closed
170

Sector Composition

Rank Sector Weight
1 Technology 16.9%
2 Industrials 13.89%
3 Financials 12.91%
4 Consumer Discretionary 10.69%
5 Healthcare 9.64%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
JOB icon
2651
GEE Group
JOB
$22.1M
$9K ﹤0.01%
13,718
-391
-3% -$213
LITS
2652
Lite Strategy Inc
LITS
$29.7M
$9K ﹤0.01%
884
+60
+7% +$2.36K
INFI
2653
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$9K ﹤0.01%
11,710
-463
-4% -$553
XTNT icon
2654
Xtant Medical Holdings
XTNT
$62.2M
$8K ﹤0.01%
12,154
-347
-3% -$227
SEEL
2655
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
$8K ﹤0.01%
4
TTOO
2656
DELISTED
T2 Biosystems, Inc
TTOO
$8K ﹤0.01%
5
MARK
2657
DELISTED
Remark Holdings, Inc.
MARK
$8K ﹤0.01%
1,398
-55
-4% -$460
DMK
2658
DELISTED
DMK Pharmaceuticals Corporation Common Stock
DMK
$8K ﹤0.01%
292
-8
-3% -$343
NBEV
2659
DELISTED
NewAge, Inc. Common Stock (Delaware)
NBEV
$8K ﹤0.01%
19,726
-563
-3% -$403
AUMN
2660
DELISTED
Golden Minerals Company
AUMN
$7K ﹤0.01%
709
-20
-3% -$226
AMPE
2661
DELISTED
Ampio Pharmaceuticals Inc.
AMPE
$7K ﹤0.01%
95
-3
-3% -$438
AVTX icon
2662
Avalo Therapeutics
AVTX
$1.05B
$6K ﹤0.01%
5
-1
-17% -$2.51K
CASI
2663
DELISTED
CASI Pharmaceuticals
CASI
$6K ﹤0.01%
1,483
-42
-3% -$330
CATX icon
2664
Perspective Therapeutics
CATX
$340M
$6K ﹤0.01%
2,009
-55
-3% -$201
COCP icon
2665
Cocrystal Pharma
COCP
$14.6M
$6K ﹤0.01%
1,057
-30
-3% -$199
INUV icon
2666
Inuvo
INUV
$16.5M
$6K ﹤0.01%
1,545
-27
-2% -$125
SLDB icon
2667
Solid Biosciences
SLDB
$911M
$6K ﹤0.01%
770
-22
-3% -$388
TRVN
2668
DELISTED
Trevena, Inc.
TRVN
$6K ﹤0.01%
35
-1
-3% -$315
OGEN icon
2669
Oragenics
OGEN
$2.47M
$5K ﹤0.01%
8
TLPH icon
2670
Talphera
TLPH
$73.7M
$5K ﹤0.01%
919
-26
-3% -$220
TOVX icon
2671
Theriva Biologics
TOVX
$10.4M
$5K ﹤0.01%
89
+13
+17% +$886
UAMY icon
2672
United States Antimony
UAMY
$993M
$5K ﹤0.01%
13,959
-398
-3% -$194
XTIA icon
2673
XTI Aerospace
XTIA
$62.7M
0
ATNX
2674
DELISTED
Athenex, Inc. Common Stock
ATNX
$5K ﹤0.01%
526
-15
-3% -$294
TYME
2675
DELISTED
Tyme Technologies, Inc. Common Stock
TYME
$5K ﹤0.01%
16,563
-222
-1% -$89

Similar funds

Victory Capital Management's Q1 2022 Portfolio in Review

As of Q1 2022, Victory Capital Management held 2,893 positions worth $100B, down 8% from $109B the previous quarter. Its ten largest holdings account for 9.8% of the portfolio.

Victory Capital Management's Q1 2022 filing shows 146 new, 1,494 increased, 995 reduced and 170 closed positions. Its largest new stake was Intra-Cellular Therapies Inc.: 932,322 shares worth $56.9M. The largest sale was iShares Core S&P 500 ETF, an estimated $1.49B.

By sector, the portfolio is most concentrated in Technology at 17% of assets, down from 18% a quarter earlier, followed by Industrials and Financials.

  • Victory Capital Management's largest Q1 2022 buy was Intra-Cellular Therapies Inc.: 932,322 shares worth $56.9M.
  • Victory Capital Management added most to MKS Inc in Q1 2022, an estimated $219M increase.
  • Victory Capital Management's biggest Q1 2022 reduction was iShares Core S&P 500 ETF, cutting an estimated $1.49B.
  • Victory Capital Management fully exited Vanguard Total World Stock ETF in Q1 2022, selling an estimated $476M.
  • Victory Capital Management's ten largest holdings make up 9.8% of its $100B portfolio in Q1 2022.
  • Victory Capital Management opened 146 new positions and closed 170 in Q1 2022.
  • Victory Capital Management's portfolio value fell 8% quarter-over-quarter to $100B.

Based on Victory Capital Management's 13F filing for Q1 2022, filed 4 May 2022.